Professor David Sharp is a neurologist and Centre Director of UK DRI Care Research & Technology, focusing on using technology to enhance the lives of people living with dementia. He is also Scientific Director of the Imperial College Clinical Imaging Facility and Associate Director of the Imperial Centre for Injury Studies. His research programme aims to improve clinical outcomes after dementia and traumatic brain injury (TBI), focusing on common cognitive impairments in domains such as memory and attention. He uses cognitive neuroscience and advanced neuroimaging to investigate the effect of brain injury on brain network function and the effects of inflammation and neurodegeneration. His has explored how new treatments of cognitive impairment can be personalised and his current work focuses on harnessing neurotechnology development to improve the lives of those living with dementia and the effects of brain injury.
et al., 2020, Clinical detection of neurodegenerative blood biomarkers using graphene immunosensor, Carbon, Vol:168, ISSN:0008-6223, Pages:144-162
et al., 2020, Author Correction: A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics., Nat Commun, Vol:11
et al., 2020, REGULAR MASS SCREENING FOR SARS-CoV-2 INFECTION IN CARE HOMES ALREADY AFFECTED BY COVID-19 OUTBREAKS: implications of false positive test results., J Infect
et al., 2020, Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial, Bmj Open, Vol:10, ISSN:2044-6055
et al., 2020, A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics, Nature Communications, Vol:11, ISSN:2041-1723, Pages:1-11